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INTRODUCTION
PREVALANCE OF ESBL PRODUCING GRAM 
NEGATIVE BACILLI IN POST OPERATIVE WOUND 
INFECTION
INTRODUCTION
 Resistant  bacteria  are  emerging  world  wide  as  a  threat  to  the 
favorable  out  come of  common  infections  in  community  and hospital 
settings. Even before the development of penicillin the first beta lactam 
anti biotic there was an emergence of resistance to betalactam antibiotics 
(Ref.30).  The  most  important  single  mechanism of  resistance  to  these 
antibiotics is due to the production of beta lactamases by gram positive 
and gram-negative organisms. The enzymes are thought to have evolved 
from penicillin binding proteins with which they show some sequence 
homology. This development was likely due to the selective pressure by 
beta lactam producing soil organisms found in the environment. Because 
of  their  increased  spectrum  of  activity  against  the  oxyimino-
cephalosporins,  these  enzymes  are  called  extended  spectrum  beta 
lactamases  which  are  capable  of  hydrolyzing  and  inactivating  a  wide 
variety  of  beta  lactam antibiotics  like third generation cephalosporin’s 
and  penicillin’s.  ESBL  producing  gram  negative  bacteria  are  of 
increasing  importance  on  a  worldwide  basis  and  these  pathogens  are 
beginning  to pose a serious threat. There is some evidence to suggest that 
over use of β lactams  has imposed a selective pressure on pathogens to 
acquire resistance genes and mutate these to confers a broader range of 
activities  (Ref.  34).  ESBLs  have  been  reported  from all  parts  of  the 
world. However there is wide variation of the prevalence even in closely 
related regions. ESBLs have been found in a wide range of gram-negative 
bacteria  and  the  majority  of  the  strains  belong  to  the  family 
Enterobacteriacae.  Enterobacteriacae  producing  ESBLs  enzymes  are  a 
clinical threat and have been associated with increased mortality in severe 
infection.      
This study was undertaken to determine the prevalence of ESBL 
producing gram negative bacilli in post operative wound infections and 
also importance of detection of these enzymes and their epidemiology.  
AIMS AND OBJECTIVES
AIM AND OBJECTIVES 
1. Collection of specimens from post operative wound infections. 
2. Inoculation of specimens onto suitable culture media for isolation of 
organisms.
3. Selection  of  gram  negative  bacilli  that  are  resistant  to  third 
generation cephalosporins.
4. Detection of ESBL from these strains using screening (Double Disk 
Synergy  Test  -  DDST)  and  confirmatory  test  (Phenotypic 
Confirmatory Disk Diffusion Test)
5. Analysis and comparison of different methods for ESBL detection.
6. To study the prevalence of ESBL producing Gram negative bacilli 
in post operative wound infections. 
 
REVIEW OF LITERATURE
REVIEW OF LITERATURE
Penicilins  and  cephalosporins  are  called  β lactam antibiotics  as 
they posses β lactam ring in their structure. Bacteria acquired resistance 
to these antibiotics by production of enzymes called β lactamases which 
hydrolyse  the  β lactam ring.  Extended  spectrum  β lactams  are  those 
antibiotics  which are not  affected  by common  β lactamases.  Enzymes 
which confer resistance to these oxy imino β lactams and mono bactams 
are called Extended spectrum β lactamases (ESBL). These are derivatives 
of common  β lactamases that have under gone one or more amino acid 
substitution(s)  near  the active site  of  the enzyme thus increasing their 
affinity  and  the  hydrolytic  activity  against  third  generation 
cephalosporins and monobactams. 
The  ESBL  enzymes  are  plasmid  mediated  enzymes  capable  of 
hydrolyzing  and  inactivating  a  wide  variety  of  β lactams  –  third 
generation  cephalosoporins,  penicillins  and aztreonam.  These  enzymes 
are the result of mutations of  TEM 1 and TEM 2 and SHV1. All of these 
β lactamase  enzymes  are  commonly  found  in  the  family 
Enterobacteriacei TEM 1, TEM 2 and SHV1 enzymes confer high level 
resistance to first generation    cephalosoporins.  Widespread use of third 
generation cephalosoporins  and aztreonam may be the major  cause  of 
mutations in these enzymes that has led to the emergence of ESBLs. The 
first ESBL isolates were discovered in Western Europe in mid 1980's and 
subsequently  in the US in the late 1980's.  The resistant  organisms are 
now a worldwide problem. The majority of ESBL producing strains are 
Klebsiella pneumoniae, K oxytoca, and Escherichia coli. Other enzymes 
in  which  the  frequency  of  ESBL  production  is  low  were; 
Enterobacter.spp, salmonella.spp, morganella.morgani, protus mirabillis, 
Serratia.marcescen and Pseudomonas.aeruginosa. 
Structure of β lactamase and mechanism of action 
All ESBLs have serine at their active sites except for a small but 
rapidly  growing  group  of  metallo  β lactamases  belonging  to  class  B. 
They share several highly conserved aminoacid sequences with Pencillin 
Binding   Proteins (PBPs).  β lactamases attack the amide bond in the β 
lactam ring of penicillin and cephalosoporins with subsequent production 
of  pencillinoic  acid  and  cephalosoporic  acid,  ultimately  rendering 
compounds antibacterially inactive. 
Classification Schemes 
Various  classification  schemes  have  been  proposed  by  many 
researchers. Classification of Sawai et al in 1986 was based on response 
to anti sera.  Amblers molecular class A – majority of ESBLs contain a 
serine  at  the  active  site  and  belong  to  these  class  characterized  by  a 
molecular  mass  of  approximately  29,000  Da.  Richmond  and  Sykes 
scheme in 1973 was on the basis of substrate profile. Extension of the 
Richmond and Sykes scheme by Sykes and Mathew in 1976 was based 
on differentiation by Isoelectric Focusing.  In the scheme proposed by 
Mitsuhashi  and Inoue in 1981 the category "cefuroxime hydrolyzing  β 
lactamases"  was  added  to  "pencillinase  and  cephalosoporinase" 
classification. Recently any clasxsificaiton scheme has been developed to 
integrate  functional  and  molecular  characteristic.  The  Bush  Jacoby, 
Medeiros  Scheme  puts  178  β lactamases  from  naturally  occurring 
bacterial  isolates  into  four  groups  based  on  substrate  and  inhibited 
profiles. 
β lactam Antibiotics 
Of  all  the  antibiotics,  β lactam antibiotics  are  among  the  most 
useful and frequently prescribed. They are so called due to the presence 
of a core  β lactam ring in their structure. Pencillins and cephalosporins 
will come under this group. Mechanism of action : Inhibition of synthesis 
of bacterial peptidoglycan cell wall. Cephalosporins : First generation – 
having G +ve and modest G -ve activity. Second Generation : Having 
some  what  better  activity  against  G  –ve  bacteria  and  some  with  anti 
anaerobe  activity.  Third  Generation  :  Less  activity  against  G  +ve 
organisms but much more activity against the Enterobacteriaceae. Fourth 
Generation : Spectrum similar to the third but having increased stability 
to hydrolysis by β lactamases. Combination of β lactam antibiotics with β 
lactamase  inhibitors  –  sulbactam/  cefoperezone  combination  is  an 
effective  and  safe  alternative  to  Aminoglycsoide  /  clindamycin 
combination  for  intra  abdominal  infections.  SHINAGAWA  et  al  – 
studied  the  efficacy  and  safety  of  sulbactam/  cefoperezone  in  the 
treatment of billary tract infections. It had an efficacy of 79.9% with the 
efficacy in patients with cholecystits, cholangits and liver abscess at 89%, 
77.3% and 21.4%.
IAKOLEV  et  al  –  studied  the  efficacy  of    sulbactam  / 
cefoperezone in wound infections. The clinical efficacy was 92% and the 
bacteriological efficacy was 76%  
 
aData  from  Ambler's  classification  and  the  classification  of  Bush 
et  al.(Ambler,  1980;  Bush  et  al., 1995)  This  table  includes  some 
simplifications. In particular, 
Group 2d includes 
(i) Molecular class A oxacillinases from Actinomadura and Streptomyces  
spp., as well as class D enzymes from gram-negative rods; (ii) hydrolytic 
activity  varies  within  each  group,  and  (iii)  sequences  remain  to  be 
determined for many enzymes included in Bush's scheme. 
b +++,  preferred  substrate  (highest  Vmax);  ++,  good  substrate;  +, 
hydrolyzed;  ±,  barely hydrolyzed; -, stable; V, variable within group; ?, 
uncertain. 
c  None  of  Bush's  group  4  enzymes  has  yet  been  sequenced;  they  are 
assumed to "l?e serine types because they lack carbapenemase activity. 

The enzyme first  associates  noncovalently  with the antibiotic to 
yield  the  noncovalent  Michaelis  complex.  The  β-lactam  ring  is  then 
attacked by the free hydroxyl on the side chain of a serine residue at the 
active site of the enzyme, yielding a covalent acyl ester. Hydrolysis of the 
ester finally liberates active enzyme and the hydrolyzed, inactive drug. 
This mechanism is followed by β-lactamases of molecular classes A, C, 
and D, but class B enzymes utilize a zinc ion to attack the β-lactam ring. 
(Livermore, 1995)
Types Of ESBLs
Most are derivatives of  TEM  or SHV enzymes . there are now > 
90 TEM type N beta lactamases and > 25 SHV type Beta lactamases. 
They are  most  often  found in E.coli  and K.pneumoniae  also found in 
proteus spp. Providencia spp. With both of these groups of enzymes a 
few point  mutations  at  selected  loci  with in  the gene  give rise  to  the 
extended  spectrum  phenotype.  TEM-1  :  First  plasmid  mediated  B 
lactamases in gram negatives described in the 1960’s found in a single 
strain of E.coli isolated from a blood culture from a patient Temoniera in 
Greece  which is  able  to  hydrolyze penicillin  and early  cephalosporins 
such  as  cephalothin  and  cephaloridine.  TEM-2: First  derivative  of 
TEM-1 had a single amino acid substitution from the original Blactmases, 
caused a shift in the isoelectric point from a PI of 5.4 to 5.6 but did not 
change the substrate profile. TEM-3: Reported in 1989 first TEM type B 
lactam ase that displayed the ESBL phenotype. SHV type Blactmase – 
another common plasmid mediated b lactam ase found in K.penumnoiae, 
E.coli  is  SHV-(sulphhydryl)  variable.  Inhibitor  Resistant  TEM 
B.Lactamases (IRT) – B.Lactamases : In early 1990’s B.Lactmases that 
were  resistant  to  inhibition  by  clavulanic  acid  were  discovered  which 
were variants of TEM-1 or TEM-2 revealed by nucleotide sequencing. 
Inhibitor  Resistant  TEM B.Lactamases  (IRT)  found mainly  in  clinical 
isolates of E.coli but also in some strains of K.pneumoniae, K oxytoca, 
P.mirabilis,  citrobater.freundii.  Although  Inhibitor  Resistant  TEM 
B.Lactamases (IRT) variants are resistant to inhibition by clavulanic acid 
and sulbactan, there by showing resistance to the  B.Lactamase –inhibitor 
combination , they remain susceptibile to inhibition by tazobactam and 
subsequently  the  combination  of  piperacillin-tazobactam  combination. 
CTXM : In recent years a new family of plasmid mediated ESBLS called 
CTXM that preferentially hydrolyze cefotaxime mainlyfound in strains of 
slamonella  enterica  serovar.Typhimurium  &  E.coli.  they  included  : 
CTXM1  (Germany,  Italy)M2  (Argentina)  M3(Poland), 
M4(Russia),M6,M7  Greece),  M5(Latvia),  M8 
(Brazil),M9,10(Spain).Tohoenzymes 1,2 prevalence in Japan. OXA: type 
enzymes are another  growing family of  ESNBLS belong to molecular 
class D and functional 2d, confer resistance to ampicillin and cephalothin, 
has  high  hydrolytic  activity  against  oxacillin  and  cloxacillin,  poorly 
inhibited  by  clavulanic  acid.  OXA  type  ESBLS  are  found  mainly  in 
P.aeruginosa. OXA 11 14 15 16 17 (Turkey) OXA 13 (France) 18 19 
28(France). 
Pathogenesis of wound infection 
Wound infection has probably always been a major complication 
of  surgery  and  Trauma.  Bacterial  Contamination  is  inevitable  but 
controlled by strict adherence to principles of asepsis.
Surgical incision itself – an initial act – which by breaching the 
skin disrupts the primary barrier to infection. Then microorganisms may 
gain access to the blood stream and deep tissues through the incision. 
Dead space may result with increased risk of infection. Areas of tissue 
ischaemia, necrosis and inadequate blood flow are created – predisposing 
to the formation of exudates and haematomas. 
Types Of Post Surgical Wounds
South ampton wound grading system
GRADE
0 Normal Healing
I
Normal Healing with mild bruising 
or erythema 
Ia Some bruising 
Ib Considerable bruising
Ic Mild erythema
II Erythema  +  other  signs  of 
inflamation 
IIa At one point 
IIb Around sutures
IIc Along wound
IId Around wound
III Clear or haemoserous discharge
IIIa At one point only ≤ 2 cms
IIIb Along wound > 2 cms
IIIc Large volume
IIId Prolonged  > 3 days
Major complications IV pus 
IV a At one point only ≤ 2 cms
IVb Along wound > 2 cms
V Deep severe wound infections with 
or  without  tissue  breakdown  - 
Hematoma requiring aspiration
Trends of Surgical wound infection 
In a study (Ref. 19) that investigated surgical wound infection rates 
in 47 hospitals from 1986 – 1990 –Surgical wound infection rates were :
After  colon  surgery  =  6.8  %  highest.  Coronary  artery  bypass 
graft = 4.6%. Gastric surgery = 4.5%.  In a comparative study of medical 
intensive  care  unit  (ICU)  patients  and  surgical  ICU  patients  ---- 
Nosocomial  infection rates  were higher in the SICU patients  (31% vs 
24%). Incidence of  post operative wound infection has fallen over the 
years ------From over 40% - for dirty wounds 1970’s to less than 30% by 
the end of the 1980’s.From 20 to 11-12% for contaminated wounds and 
from 9 to 7-8% for clean contaminated wounds.
Common Surgical Pathogens
In  one  study  :  33%  of  all  surgical  infections  caused  by  staph 
aureus.  most  common  wound  pathogens  after  intrabdominal   surgery 
were : Enterococci, Entrobacter, Spp, E.coli. 
48.4% of incisional wound isolates = Gram positive organisms 
Type of operation Anticipated  Pathogen
Open  heart  Surgery,  Vascular 
surgery
S.aureus,  Coagulase  positive 
staphylococcus GNB
Lower Extremity amputations S.aureus,  Coagulase  positive 
staphylococcus GNB
Gastroduodenal Streptococci,  Bacteroides, 
Spp.colifoms
Billary Tract high risk Coliforms, enterococcus 
Vaginal/Abdominal 
hysterectomy/Cessarian Section
Group B, Strptococi, Enterococcis, 
anaerobes Enerobacteriaceae 
Colorectal, Appendicetomy Enerobacteriaceae, Anaerobes
Cranitomy / Lamiinectomy S.  aurues  coagulase  positive 
staphylococcus.
SSI – SURGICAL SITE INFECTION RATES BY WOULD 
CLASSIFICATION AND NNIS SYSTEM RISK INDEX
Incision classification Risk index category(% infection)
0 1 2 3
Clean 1.0 2.3 5.4 -
Clean contaminated 2.1 4.0 9.5 -
Contaminated - 3.4 6.8 13.2
Dirty infected - 3.1 8.1 12.8
Over all 1.5 2.9 6.8 13.0
(Ref : John .L.Cameron current surgical therapy 8th Edition  
NNIS  –  National  Nosocomial  infection  surveillance.  Post  operative 
wound infections constitutes to major source of morbidity and mortality 
for surgical patients. Surgical wound infections divided into:
1. Incision involving tissues above facia – 60%
2. Deep (invaliding tissue at or below facia)
3. Nosocomial surgical wound infections – 40%
Variables increasing risk of post Operatives infection
Patients  variables -  Age  over  60yrs  Malnutitirtions,  obesity,  Diabetes 
mellitus,  Radiation  therapy,  steroid  therapy,  malignancy,  Immuno 
Suppressive therapy. 
Preoperative  variables -  Duration  of  preoperative  hospitalization, 
Duration of Surgery, present of hematoma, use of drains, repeat operation 
(during same operation), insertion of foreign body or implant.
 
ESBL Detection Techniques 
ESBL Detection Techniques : (Ref. 30)  
Clinical Micro biology Techniques 
1. Standard NCCLS interpretive criteria.
2. NCCLS ESBL Confirmatory Test
3. Double Disk approximation Test
4. Three Dimensional Test
5. E-Test, ESBL Strips 
6. Viteke ESBL Test
Molecular Detection Techniques
1. DNA Probes
2. PCR
3. Oligotyping
4. PCR-RFLP
5. PCR-SSCP
6. LCR
7. Nucleotide Sequencing
Several  ESBL detection  test  are  based  on the  KIRBY-BAUER DISK 
DIFFUSION  Methodology 
Routine antibiotic susceptibility testing methods are not capable of 
detecting  ESBL resistance  without  modification.  There are  chances  of 
ESBL  producers  likely  to  be  reported  falsely  as  susceptible  to  the 
cephalosporins,unless specific  ESBL screening and  confirmation tests 
are carried out. 
ESBL Detection is a Two-Step Process 
A  screening  step  with  an  indicator  cephalosporin  to  indicate 
possible ESBL production followed by a phenotypic confirmatory test. 
(Ref.34).
To establish the prevalence of ESBL strains in clinical isolates we 
have to examine the available phenotypic ESBL detection methods and to 
develop  an  optimal  protocol  for  routine  ESBL  testing.  Two  different 
protocols were used : (Ref. 34)
Protocol-1 :  Three test panels were used  for ESBL detection using the 
NCCLS method.   (K.pneumoniae  ATCC 700603 was used as  positive 
control for ESBL). 
1. ESBL –E-TEST PANEL :   Cefepime,ceftazidime,cefotaxime, each  + 
clavulanate.
2. CONVENTIONAL  PANEL  OF  ESBL  COMBINATION  DISCS  –   
Cefpodoxime, ceftazidime,cefotaxime each +  clavulanate.
3. EXTENDED PANEL OF ESBL COMBINATION DISCS :  -
Cefpirome (oxoid) and  cefepime (MAST),each + calvulanate. 
Cefoxtin (oxoid) disk was used for detecting AMPC production. 
Protocol : 2 :  Single plate disc approximation method. Four substrates 
cefpodoxime, ceftazidime, cefotaxime, cefepime disks were placed using 
a template approximately 2.5 cm from a co-amoxiclav disk in the center 
on a single Muller Hinton Agar Plate inoculated with a 0.5 McFarland 
suspension of  isolate to be tested.  Use of more than one substrate for 
screening  is  recommended  by  NCCLS.  The  use  of  Cefepime  permits 
ESBL detection in isolates simultaneously Producing Ampc.
Double Disk Approximation Test (Ref. 30) 
1. Described by  Jarlier et al In this test the organism is swabbed onto 
a  Mueller-Hinton  Agar  Plate.  A  susceptibility  Disk  Containing 
amoxicillin Clavulanate is placed in the center of the plate and Disk 
Containing one of the Oxyimino -  β lactam antibiotics are placed 
30 mm (center to center)  from the amoxicillin - Clavulanate Disk, 
Enhancement of the Zone of Inhibition of the Oxyimino-  β lactam 
caused  by  the   Synergy  of  the  Clavulalate  in  the  amoxicillin-
Clavulalate  disk is a positive test. The Sensitivity of the test was 
increased by the reducing the distance between the disks to 20 mm 
in this study.( Ref : Bradford volume 14 no.4,2001) 
2. Jacoboy and Han test : in which 20 micro grams of sulbactam was 
added  to  susceptibility  disks  containing  one  of  the  oxyimino  B 
lactam antibiotics an increase of 5 mm in the zone of inhibition in a 
disk  containing  sulbactam-  compared  to  the  drug  alone  was 
considered a positive test. 
3. Three  Dimensional  test  by  Thomson  and  sanders  :  Following 
inoculation  of  the  test  organism  onto  the  surface  of  a  Mueller 
Hinton  agar  plate,  slit  is  cut  into  the  agar  into  which  a  broth 
suspension  of  the  test  organism  is  introduced.  Subsequently 
antibiotic disks are placed on the surface of the plate 3mm from the 
slit.Distortion  or  discontinuity  in  the  expected  circular  zone  of 
inhibition is considered a positive test.    
4. Phenotypic Confirmatory Double Disk Diffusion test : The NCCLS 
recommended the use of ceftazidime in combination with clavulanic 
acid.  Perform  the  antibiogran  using  Muller-Hinton  agar  and 
Mcfarland 0.5 inoculum. Test both ceftazidime  +  clavulanic acid 
and  ceftazidime  alone.  An  increase  in  zone  diameter  for  the 
combination  of  ceftazidime  +  clavulanicacid  compared  to 
ceftazidime.alone  of  more  then  >5  mm  is  confirmatory   of  the 
presence of   ESBL.
NCCLS  Screening  and  Confirmatory  tests  for  ESBLS  : 
(K.pneumoniae, K oxytoca, E.coli) (Ref .34)
Step 1 : ESBL- Screening (BP=Break point)
Disc
R.
(BP.mm)
S.(BP.mm)
ESBL 
Screening 
BP(mm)
Cefpodoxime   10 mg 17 27 17
Ceftazidime      30mg 14 18 22
Aztreonam        30mg 15 22 27
Cefotaxime       30mg 14 232 27
Ceftriaxone       30mg 13 21 25
Zone diameter less than or equal to ESBL Screening BP for any 
one  of  the  above  antibiotics  MAY  indicate  ESBL  production.  Go  to 
Step 2.
Step 2 : ESBL Confirmatory Test
Discs Interpretation
Ceftazidime  30 mg
Ceftazidime  +  Clavulanic  acid   30/10 
mg
AND
Cefotaxime   30 mg
Cefotaxime  + Clavulanic  acid    30/10 
mg
A  5  mm  increase  in  zone 
diameter 
For  EITHER  antibiotic  tested 
in  combination  with 
Clavulanic  acid  .  Versus  it 
zone  when  tested  alone 
confirms ESBL production.
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Table  2  A.  (Continued)  Screening  and  Confinnatory  Tests  for  ESBLs  in  Klebsiella 
pneumoniae, K. oxytoca, and Escherichia coli.
Method Initial Screen Test Phenotypic Confinnatory Test
Medium Mueller-Hinton Agar Mueller-Hinton Agar
Antimicrobial Disk 
Concentration
Cefpodoxime 10 micro g or 
ceftazidime 30 micro g or 
aztreonam 30 micro g or 
cefotaxime 30 micro g or 
ceftriaxone 30 micro g or 
(The  use  of  more  than  one 
antimicrobial  agent  for 
screening  improves  the 
sensitivity of detection). 
ceftazidime 30 micro g 
ceftazidime/clavulanic acida 30/1 0 
micro g I and 
cefotaxime 30 micro g 
cefotaxime /clavulanic acida 30/1 0 
micro g 
(Confinnatory  testing  requires  use  of 
both cefotaxime and ceftazidime, along 
and  in  combination  with  clavulanic 
acid. 
Inoculum Standard disk diffusion 
recommendations
Standard disk diffusion 
recommendations
Results Cefpodoxime  zone  < 22  mm 
Ceftaz~dime  zone  < 22  mm 
Aztreonam  zone   < 27  mm· 
Cefotaxime  zone  < 27  mm 
Ceftriaxone zone      <   25 mm 
= suspicious for ESBL 
production
A > 5 mm increase in a zone diameter 
for either antimicrobial agent tested in 
combination  with  clavu1anic  acid 
versus  its  zone  when  tested  alone  = 
ESBL (e.g., ceftazidime zone = ESBL 
(e.g.,  ceftazidime  zone  =  16; 
ceftazidime/clavulanic acid zone= 21) 
QC Recommendations E. coli ATCC 25922 (see 
control limits in Table 3) 
Kleb'siella pneumomae ATCC 
700603 : 
Cefpodoxime zone 9-16 mm 
Ceftazidime zone 10-18 mm 
Aztreonam zone 9-17 mm 
Cefotaxime zone 17-25 mm 
Ceftriaxone zone 16-24 mm
E. coli ATCC 25922 : < 2 mm increase 
in  zone  diameter  for  antimicrobial 
agent tested alone versus its zone when 
tested  in  combination  with  clavulanic 
acid. 
Kebsiella pneumoniae ATCC 700603 : 
> 5  mm  increase  in  ceftazidime  / 
clavulanic acid zone diameter; 
> 3  -  mm  increase  in  cefotaxime  / 
clavulanic acid zone diameter.
Controls :
E.coli ATCC  25922(-ve QC)
K.pneumoniae ATCC 700603 (+ve QC)
Quality  Control  :  (Ref.35)  The  NCCLS  recommends  Klebsiella 
pneumoniae  ATCC  700603  as  an  ESBL  producing  QC  control(+ve 
control)  &  Escherichia.coli  25922-as  a  negative  control  in  ESBL 
confirmation  tests.  zones  of  the  cephalosporins  and 
cephalosporins+Clavulanate disks for ESBL negative  E.coli should be 
equal  or  at  worst  within  + 2  mm.Any  greater  difference  implies 
malfunction  or  deterioration.   This  screen  is  than  followed  by  a 
phenotypic confirmatory test that consist of determining MICs of either 
cefotaxime or ceftazidime with and without the presence of  clavulanic 
acid 4 µ gm/ml.
  
ETEST :  Etest  ESBL  strip  carries  two  Gradients  on  the  one  end 
Ceftazidime on the opposite end Ceftazidime + Clavulanic acid. MIC is 
interpreted   as the point of intersection of the inhibition ellipse with the E 
test Strip edge. Ratio of Ceftazidime MIC and Ceftazidime + Clavulanic 
acid MIC equal to or greater than 8 indicates the presence of ESBL.
MIC Reduction Test : An  8 fold reduction in the MIC of Cephalosporin 
in  the  presence  of  clavulanic  acid  indicates  –  production   of  ESBL. 
(Ref .11). For MIC testing  - A decrease of  >3 doubling dilutions in an 
MIC for either Cefotaxime  or Ceftazidime  tested in combination with 
4 µ gm /ml micro gram clavulanic acid vesus the MIC when tested alone 
confirms an ESBL producing Organism.(Ref.37). In one study (Ref.24) 
Hansotia et al where 2 micro gram per ml of clavulanic  acid as been 
recommended.  The  minimum  inhibitory  concentrations  of  (MIC)  of 
Ceftazidime, Cefotaxime and Ceftriaxone have to be determined for each 
of the resistant Isolates by AGAR Dilution method. The inoculum has to 
be  standardized  which  is  essential  to  provide  reproducible  MICs.  A 
properly prepared Mc Farland 0.5 turbidity standard is helpful to achieve 
the correct working inoculum of 107  cfu / ml. After inoculation with a 
multi point inoculator, delivering 1-2 microl. The final inoculum on the 
agar surface will be approximately 104 cfu / spot. For broth dilution MICs 
the final Inoculum should be 105 cfu/ml.
A method of preparing antibiotic dilutions for MICs  Ref : Mackie 
& Mccartney practical medical microbiology 14th edition page162.
 Three stock solutions were prepared in step 1 and used to prepare 
the working dilutions in steps 2 -4 before addition of agar or broth in 
step5.
Step 1 :   I       II III
Initial Solution     9 ml + 1ml  9.9 ml + 0.1 ml
10ml Distilled Water 
(10,000 mg/ltr)       (1,000 mg/ltr)   (100mg/ltr)
STEP 2 
(10,000 mg/ltr)256 µ ltr 128 µltr 64 µltr 32 µltr
128mg/ltr 64mg/ltr 32mg/ltr 16 mg/ltr
STEP 3 
(1,000 mg/ltr) 160 µltr 80 µltr 40 µltr
 8mg/ltr 4mg/ltr 2mg/ltr
STEP 4 
(100 mg/ltr) 200 µltr 100 µltr 50 µltr
1mg/ltr 0.5mg/ltr 0.25mg/ltr
STEP 5 
 20ml agar was added to all dilution bottles including control bottle 
to give 10 different concentrations of each antibiotic in MHA and mixed 
before pouring plates or dispensing broth. 
MIC Determination :   (Ref.24)    (Hansotia.et.al.,)   The  minimum 
inhibitory  concentrations  (MICs)of  cefotaxime,  ceftazidime  has  to  be 
determined for  each of  the resistant  isolates  by Agar  Dilution method 
using an inoculums size of 105 CFU/ML. Serial two fold dilutions of each 
test antibiotic were incorporated in Mueller Hinton Agar to give 13 or 10 
different  concentrations of  each antibiotic  in  MHA. (0.03125-128 4  µ 
gm / ml. In one study (Ref. 8) - eight two fold dilutions of test antibiotic 
has been recommended.
MIC Reduction Test (Hansotia. et.al.,)
The  MICs  of  Third  Generation  Cephalosporins  test  antibiotics 
determined earlier for  each of the 45 resistant isolates has to be noted. 
Similarly the MICS of each 3 generation cephalosporins, test antibiotic 
combined with 4  µgm/Ml of clavulanic Acid has to be determined for 
each resistant isolate at different concentrations. (0.0625 – 4 µgm/Ml) of 
test  antibiotic  in  MHA.  The  reduction  in  MIC was  calculated  by  the 
fractional. Inbitory concentrations (FIC) index. (Ref. 24)
FIC Index = .3
3
aloneAntibioticTestGCofMIC
AcidclavulanicwithcombinedantibiotictestGCMICof
An index of less than 0.5 was considered as evidence of synergism
II Molecular Techiques 
1. DNA Probes : Early detection of B. Lactamase genes was performed 
using DNA probes, that were specific for TEM  & SHV. enzymes. DNA 
sequencing  has  become  the  gold  standard  for  analyzing  novel  beta 
lactamase genes 2.  Obligo Typing  -  Developed by the Queltelle etal. 
Used to discriminate between TEM 1 and TEM 2 3. PCR – PCR with 
oligonucleotide  primers  that  are  specific  for  a  betalactamase  gene. 
Obligonucleotide  primers  can  be  chosen  from  sequences  available  in 
public  databases  such  as  Genbank.  4.  PCR  –  RFLP  add  Restriction 
Fragment length prolymophism analysis to PCR. 5. PCR – SSCP – Single 
strand conformational  polymorphism.  6.  LCR :  Ligase  chain  reaction. 
7.  ISO  electric  Forcussing  Analysis.  8.  PFGE  –  Pulse  field  gel 
electrophoresis – An epidemiological tool is used to study  clonal spread 
and hospital outbreak.
Epidemiology 
ESBLs are now a problem in hospitalized patients worldwide. The 
frequency of their occurrence in clinical infection is increasing globally. 
It Ranges from  5% In   Canadian Hospitals  to > 25 % in Western Pacific 
and > 50 % in Indian Hospitals.
 
The  source  of  ESBL  :  Hospital  or  community  :  (Ref.  31). 
Community acquired outbreaks of ESBL infections are emerging due to 
increasing use of broad spectrum antibiotics in the community and due to 
large number of ESBL positive patients who carry the organisms from 
hospitals to community. Out breaks may be associated with inadequately 
disinfected  equipments  or  contaminated  surface  levels  –  Hand  Touch 
Sites – Hands are chief route whereby patients acquire hospital strains 
and hand washing programmes for staff are likely to impact on hospital 
acquired infection rates. 
Molecular epidemiology (Ref. 36) : The mechanism of spread may 
be  clonal  strain  dissemination,   clonal  plasmid  dissemination  and 
selection among polyclonal strains or both. The methods of transmission 
includes  –  clonal  dissemination  of  an  ESBL  producer  strain  or  the 
dissemination of a plasmid carrying an ESBL gene. Selective antibiotic 
pressure then leads to colonization of patient's skin and bowel with a risk 
of subsequent infection. Thus fecal colonization may play a critical role. 
Out  breaks  may  be  associated  with  procedures  –  catheterization  and 
contamination of medical  devices.  Through health care personal hands 
spread  then  appears  to  occur.  Because  of  patient  colonization, 
environmental contamination and hand transmission endemic strains may 
persists  in  health  care  settings  for  years.  To  prevent  the  spread  and 
outbreak  of  ESBL  producing  microorganisms,  proper  infection 
prevention and control practices are essential. 
Surveillance : Systematic method of collecting, consolidating, analyzing 
and  distributing  data  with  critical  information  on  the  distribution  and 
determination of a given disease or event. 
Best  practices   :  The  following  practices  are  organized  into  five 
categories. Antibiotic stewardship – Infection control professionals play a 
role,  Surveillance  and  screening,  Precautions,  Hand  hygiene  and 
antisepsis, Disinfection / environment.
  Surveillance and screening : Preventing and controlling the spread of 
ESBLs is having an effective  and consistent  approach to surveillance. 
The  activity  of  surveillance starts  with micro  laboratory reporting and 
then an assessment of patient's risk factors for colonization. Screening of 
high  risk  target  population,  Neutropenic  elderly  patients,  transplant 
recipients,  premature  neonates,  post  gastrointestinal  surgery,  prolonged 
extensive antibiotic use (Cephalosporins) and high risk unit admissions, 
ICUS,  Hematology,  oncology  units,  transplantation  units,  are  all 
necessary. 
  
    The frequency of occurrence of an outbreak is dependent whether 
the  successful  clone  begins  to  survive  within  hospitals  and causes  an 
outbreak. These outbreaks are often fueled by the large number of patient 
transfers between units & between hospitals. 
Specific Risk Factors which will predispose to an outbreak were : Length 
of hospitals stay, time in the ICU, intubation and mechanical ventilation, 
urinary or arterial catheterization, prior hospitalisation, old age 60 years, 
Prior  use  of  Antibiotic   therapy  within  previous  3  months,  Males, 
debilitated patients confined to bed, many of the patients infected with 
ESBLs are found in ICUs, surgical and neonatal wards.
There is a need to study the role of environment, animal sources, 
hospitals sludge play in the transmission of ESBLS between the species 
and inter and intra  hospital spread. Efficient infection control practices 
for containment of outbreaks – will require intervention strategies such as 
restriction of the use of Oxyimino- cephosporins and Antibiotic cycling. 
A  successful  approach  to  the  control  of  the  spread  of  ESBL 
producing  organisms  involved  switching  to  different  classes  of  broad 
spectrum antibiotics. Two most successful replacement antibiotics have 
been imipenem and piperacillin – tazobactam (Ref. 30)
Molecular  methods  for  studying  the  epidemiology  of  the  strains 
involved in outbreaks  are 
Plasmid Profiles 
Pulse field gel electro phoresis 
Ribotyping 
RAPD – Random Ampliphied Polimorphic DNA
AP – PCR – Arbitrarily Primed - PCR
Prevention of spread of ESBL positive organisms in the ward 
Infection control precautions – barrier nursing, cohorting of patients 
and nurses. Contact  precautions – use of disposable gloves, gowns and 
strict attention to handwashing. Infection control policy.Formulation of 
an appropriate hospital antibiotic policy will be necessary. 
Co resistance  to  quinolones  and  amino  glycosides  are  common. 
Usage of quinolones should be restricted as far as possible as they are 
strong selectors of ESBL producers. 
Treatment  :  Treatment of ESBL producing strains of entrobactriaceae 
has emerged as a major challenge in hospitalized as well as in community 
based  patients.  These  organisms  are  responsible  for  a  variety  of 
infections. 
Urinary tract infection 
Septicemia
Hospital acquired Pneumonia
Intra abdominal abscess
Brain abscess
Device related infections
Management decisions in the treatment of ESBL producers
Non antibiotic approach, Removal of the source of the infection –
Removal  or  replacement  of  the  foreign  body  or  prosthetic  device 
becomes necessary because infections of surgical implant and devices are 
associated  with  bio-film  formation.  Removal  of  a  ESBL  colonized 
intravascular line (Central venous  catheter – Peripheral  venous catheter) 
change of a colonized indwelling urinary catheter drainage of an intra 
abdominal abscess removal of an infected prosthetic device, heart, valve 
prosthetic joint. Combination of imipenem + Amikacine was great in the 
treatment of life threatening infections like septicemia hospital acquired 
peneumonia intra visceral abscess due to faster killing rates of amikacin.
A few Beta lactams, 7 Alfa methoxy cephalosphorins – Cefoxitin, 
Cefotetan are effective. Beta Lactam, β lactamase inhibitor combination 
is very useful.Organisms such as Klebsiella pneumoniae -  may become 
deficient  in the crucial  outer membrane proteins thereby rendering the 
Beta  lactam  –  Beta  lactamase  inhibitor  combination  clinically  in 
effective.
OPAT  –  Outpatient  Parentral  Antibiotic  Therapy  :-  Intra  venous 
administration  of  ertapenem  and  aminoglycosides  (Gentamicin)  once 
daily has given greater options in OPAT setting. (Ref. 31)
MATERIALS AND METHODS
MATERIALS AND METHODS
The  study  was  conducted  in  the  Department  Microbiology, 
Coimbatore Medical College Hospital, Coimbatore from October 2004 to 
September 2005. 
The subjects considered for our study were 120 patients admitted 
in the post operative surgical wards with surgical wound infections and 
those  who  had  inclusive  criteria  of  Grade  IV  (pus)  of  south  ampton 
wound grading system. The study material consist of wound swabs from 
post  operative surgical wound site.  Samples were collected from them 
using the following protocol – sample collection technique - The wound 
area was wiped with sterile saline (or 70% alcohol) swabbed along the 
leading  edge  of  the  wound.  Wound  swabs  were  collected  from  120 
patients with clinical infected wounds and 15 from out patients attending 
the Review OPD (After discharge surveillance). 
In  each case  two swabs  were taken from the clinically  infected 
wound site, on the third post operative day i.e. at the time of first change 
of  dressing,  used for  culture.  From the other  swab smears were made 
gram stained and examined microscopically. After discharge surveillance 
swabs  – two were taken one for  bacterial  culture and other  for  smear 
preparation.  When  Gram  stained  smears  were  examined  under  the 
microscope,  gram negative  rods  were  seen  (GNB).  All  the  specimens 
were inoculated onto the following media.  Nutrient Agar, Blood Agar, 
Macconkey Agar. Incubated at 37oC for 24 hours. After incubation for 
24 hours the plates were examined for growth and the morphology of the 
colonies  has  been  observed.  The  gram negative  bacilli  colonies  were 
tested for a panel of biochemical tests. 
Based on colony morphology and a panel of biochemical tests – the 
organisms  were  identified  upto  the  species  level.  The  antimicrobial 
susceptibility of all the isolated aerobic bacterial organisms was done by 
KIRBY BAUER Disk diffusion method using Mueller-Hinton –Agar and 
the following anti microbial disks.  
Amikacin 30 micro gram Cefotaxime – 30 micro gram
Gentamicine 10 micro gram Ceftazidime – 30 micro gram
Ciprofloxacine 5 micro gram Ceftriaxone – 30 micro gram
Oflaxacine 5 micro gram Co-trinaxazole 25 micro gram
Inoculum standardization : (According to NCCLS ( KIRBY-BAUER))
When  using  the  technique  of  KIRBY-BAUER,  inoculum  is 
standardized according to the method described by the NCCLS, which 
normally results in more dense growth and therefore smaller inhibition 
Culture  Plates  (MacConkey  Agar)  showing  Escherichia  coli  (LF), 
Klebsiella  pneumoniae  (MLF),  Proteus  mirabilis  (NLF)  and 
Pseudomonas  aeruginosa  in  nutrient  Agar  (bluish  green  pigment 
production). 
BIOCHEMICAL TESTS
       
Escherichia coli
1. Indole = +ve 
2. Gulcose = +ve
3. Lactose = +ve
4. Sucrose = +ve
5. Manitol = +ve
6. Citrate utilization = - ve
7. Urease production = -ve
8. TSI = A/A = Acid slant / Acid butt and 
gas production 
9. Methyl red test = +ve
10. Voges – proskauer test = -ve
Proteus mirabilis
Klebsiella pneumoniae
1. Indole = -ve 
2. Gulcose = +ve (Acid and Gas)
3. Lactose = +ve
4. Sucrose = +ve
5. Manitol = +ve
6. Citrate utilization = + ve
7. Urease production = +ve
8. TSI = A/A = Acid slant / Acid butt 
and gas production 
9. Methyl red test = -ve
10. Voges – proskauer test = +ve
Pseudomonas aeruginose 
Escherichia coli
11. Indole = -ve 
12. Gulcose = +ve (Acid and Gas)
13. Lactose = -ve
14. Sucrose = -ve
15. Manitol = -ve
16. Citrate utilization = - ve
17. Urease production = +ve
18.TSI = K/A = Alklaline slant / Acid butt, 
gas and H2S production +ve
Proteus mirabilis
Klebsiella pneumoniae
11. Indole = -ve 
12. Gulcose =  Only Acid 
13. Lactose = - ve
14. Sucrose = - ve
15. Manitol = - ve
16. Citrate utilization = + ve
17. Urease production = +ve
18.TSI = K/K = Alklaline slant and butt 
negative for H2S and  gas production.
Pseudomonas aeruginose 

zones than for semi confiuent growth. Two to three colonies have been 
suspended into 10 ml physiological saline and thereafter diluted 0.1 ml / 
10 ml. For Enterobacteriaceae and other gram negative rods 1 to 2 drops 
(for 9cm plate 3 to 4 drops for 14cm plate) of the final suspension have 
been taken and applied on to the Agar surface and distributed with a glass 
rod. The open plate is then dried at 35-37oC for 10-15 minutes before the 
disks are placed onto the Agar surface. 
The plates were incubated at 37oc for 24 hours and the Diameter of 
the  zone  of  inhibition  for  each  antimicrobial  disk  was  measured  and 
recorded  as  resistant,  intermediate  and  susceptible  according  to  the 
standard NCCLS interpretative criteria. Those isolates which were gram 
–ve and showed resistance to Cefotaxime, Ceftazidime, Ceftriaxone were 
included in this study. 45 isolates which were gram –ve and were found 
to be resistant to all 3 GC antibiotics were selected for further study. All 
of  them  were  screened  and  confirmed  for  ESBL  production.  The 
following methods were adopted for ESBL detection. 
1. Screening by Double Disk approximation test 
2. Confirmation  by  phenotypic  confirmatory  Double  Disk 
Diffusion test.
1. Double Disk approximation test : In this test the organism is swabbed 
onto a Mueller – Hinton Agar Plate. A susceptible disk containing 
DDAT shows  enhancement in the zone of cefotaxime Disk on the side 
facing the Augmentin indicating the production of ESBL by the isolate.
NCCLS confirmatory test – shows increase in zone diameter more than 
5mm  around  the  ceftazidime  plus  clavulanic  acid  disk  compared  to 
ceftazidime disk alone indicating the presence of ESBL in the isolate.

Amoxycillin 20µg and 10µg Clavulanic acid (Augmentin) is placed in the 
center  of  the  plate.  Disk  containing  one  of  the  (30µg)  oxyimino 
betalactum   antibiotics  are  placed  30mm  center  to  center  from  the 
Amoxycillin – Clavulanate Disk incubated at 37oC for 24 hours. It was 
observed  that  the  zone  size  around  the  test  antibiotic  was  increased 
towards the Augmentin Disk. 
2. Confirmation by phenotypic confirmatory Double Disk Diffusion 
test :
This  was  done  as  per  the NCCLs recommendations.  On Muller 
Hinton  Agar,  Four  Disks  containing  cefotaxime  (30µg),  cefotaxime  / 
clavulanic  acid  (30µg  /  10µg),  ceftazidime  (30µg),  and  ceftazidime  / 
clavulanic acid (30µg / 10µg) were used. There was a > 5mm  increase in 
zone  diameter  for  either  antimicrobial  tested  in  combination  with 
clavulanic acid versus its zone when tested alone, which confirmed ESBL 
production. ESBL was deducted in 20 isolates of Escherichia.coli  and 25 
isolates of Klebsiella pneumoniae (Table IV) and in none of the isolates 
of Proteus Spp and Pseudomonas.aeruginosa. 
MIC Determination : Agar Dilution Technique – All antimicrobial agents 
were prepared  freshly  before  each use  to  avoid any loss  of  potency. 
MHA was prepared and sterilized at 121oC for 15 minutes. The pH of 
each batch of MHA was checked when the medium was prepared – The 
medium  is  allowed  to  cool  to  45-50oC  in  a  water  bath.  Appropriate 
dilutions of antimicrobial  agents were added to molten test agars.  The 
agar and anti microbial solutions were mixed thoroughly and the mixture 
was poured into petri dishes to result in a agar depth of 3-4 mm. 
Control plates – Drug free plates prepared from the base medium was 
used as growth controls. 
Antimicrobial concentration and inoculum preparation – serial two fold 
dilutions of test antibiotic were incorporated in Muller – Hinton   Agar to 
give 13 different concentrations of each antibiotic in MHA (0.03125-128 
µgm/ml). The test inoculum was prepared with an overnight growth of 
each  isolate,  which  was  adjusted  to  a  turbidity  equivalent  to  0.5  Mc 
Farland standard.  Test  organism was inoculated  in  each concentration 
Agar dilution plate with one µl of this suspension (105 CFU/ml) and the 
plates were incubated at 37oC. The MICs of cefotaxime, ceftazidime for 
each of the resistant isolates were determined and noted. Similarly the 
MICs of cefotaxime, ceftazidime combined with 4µgm/ml of clavulanic 
MIC of cefotaxime by Agar dilution method for ESBL producers.
1. Photograph showing cefotaxime (cef) antibiotic dilution.
2. MIC determination by Agar dilution method.  
3. Photograph showing   Gram Negative Rods (GNR). 

acid,  were  also  determined  for  each  resistant  isolate  at  different 
concentrations (0.0625 -4µgm/ml). It was found that there was a decrease 
of  >3  doubling  dilutions  in  MICs  of  cefotaxime,  ceftazidime  with 
clavulanic acid compared to the MICs of  cefotaxime, ceftazidime.
RESULTS
RESULTS
Table -I
Sex distribution among post surgical patients in this study
Sl.No Sex
Total Number of 
patients
Percentage of Post 
surgical patients
1 Male 76 63.33%
2 Female 44 36.67%
The total number of patients screened were 120 of which Males = 
76 = 63.3%, Females = 44 = 36.67% (Table-I).
Chart -I 
Sex distribution among post surgical patients in this study
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Table -II
Age distribution among post surgical patients in this study
Sl.No Age Group
Percentage of Post surgical 
patients
1 25-35 years 25.4%
2 36-55 years 54.1%
3 Above 60 years 20.5%
Patients included in this study were of 25-30 years (25.4%), 36-55 
years (54.1%), above 60 years (20.5%) (Table – II)
Socio Economic Status : Patients included in this study were belong to 
low socio economic group.
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Table - III
Distribution of the various organisms isolated form from post 
operative surgical wound infections
Organism Percentage
Escherichia.coli 35.83
Klebsiella.pneumoniae 43.33
Proteus spp 14.17
Pseudomonas.aeruginosa 6.67
A total of one hundred and twenty organisms were isolated. They 
were  Escherichia.coli = 43, Klebsiella.pneumoniea = 52, Proteus.spp = 
17, Pseudomonas.aeurugilosa=8 (Table-III)
Chart-III 
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Table -IV
Distribution of ESBL +ve Strains among the different organisms 
isolated
Organism
Number of 
Organisms 
isolated
Number of 
ESBL +ve 
strains
Percentage 
of ESBL 
Strains
Escherichia.coli 43 20 46.50%
Klebsiella.pneumoniae 52 25 48.07%
Proteus.mirabilis 17 - -
Pseudomonas.aeruginosa 8 - -
Acinetobacter - - -
Citrobacter - - -
Enterobacter - - -
Morganella morgani - - -
TOTAL 120 45 37.50
Out one hundred and twenty isolates 45 were found to be ESBL 
producers (37.50% of the total isolates) Escherichia.coli = 20 (46.50%), 
Klebsiella.pneumoniea = 25 (48.07%) (Table-IV)
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Number of ESBL  positive isolates detected among isolates from post operative wound infections
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Chart - VI  
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ESBL  producing  gram  negative  bacilli  -  screening  versus 
confirmatory test
When the results  of the initial  screening tests  for  the two major  gram 
negative isolates were compared with the results of the confirmatory test 
for  ESBL test  it  was found that  the majority  of the isolates that were 
positive in the screening in the screening test were also positive by the 
confirmatory testing, although some of the isolates that were positive in 
the screening test were negative for ESBL productions when tested by the 
confirmatory method. (Table-V)
Table -V
ESBL producing gram negative bacilli - screening  versus 
confirmatory test
Confirmatory 
Test Result
Isolates Positive on Screening 
Test
Isolates Negative on 
Screening Test
E-coli Klebsiella Spp E-coli Klebsiella Spp
Positive 20   (46.50%) 25  (48.07%) 0 0
Negative 3   (6.9%) 4    (7.6%) 0 0
Table VI
Antimicrobial  resistance  of  ESBL  producing  isolates  to  Third 
Generation Cephalosporins
Organism CTAX CTRX CTAZ
Escherichis .coli (20) 42.17% 40.01% 41.97%
Klebsiella 
pneumoniae (25)
43.45% 38.83% 43.41%
Antimicrobial Resistance Pattern of ESBL producing isolates (45) 
to  CTAX,  CTRX,  CTAZ,  showed  resistance  percentage  of  85.62% 
(CTAX),  78.84% (CTRX),  85.38% (CTAZ).  In  this  study  among  the 
betalactum antibiotics  the  maximum degree  of  resistance  was  seen  to 
ceftazidime, cefotaxime and then ceftariaxone. 
Table VII
Antimicrobial resistance of ESBL producing isolates to 
Non beta lactum antibiotics
Organism OFX Ciprofloci
n
Gentamici
n
Co-trimaxzone
Escherichis .coli 
(20)
36.77% 37.81% 36.77% 42.17%
Klebsiella 
pneumoniae (25)
41.60% 48.38% 40.69% 47.15%
Antimicrobial resistance of ESBL producing isolates to non beta 
lactum  antibiotics  were  also  studied  and  noted  that  among  ESBL 
producing isolates (45) there was associated high level co-resistance to 
Co-trimaxzone  (89.32%),  ciprofloxcine  (86.19%),  oflaxacin  (78.37%), 
and gentamicin (77.46%). 
Table VIII
Antimicrbial Susceptibility Pattern of ESBL Positive Isolates
to Non Beta lactam antibiotics
Organism R/All S/G S/Cip S/AK S/OFX S/COTX
Escherichia.coli (20) - 10% 5% 100% 10% 5%
Klebsiella 
pneumoniae (25)
-
8% 8% 88% 16% -
Antimicrbial  Susceptibility  Pattern  of  ESBL Positive  Isolates  to 
Non Beta lactam antibiotics were also studied and found that  most  of 
them were found to be highly susceptible to amikacin, but the level of 
susceptibility  to  co-trimaxazole  (5%)  quinolones  (cipfloxacin  13%, 
oflaxacin 26%) and gentamicin 18% were found to be comparatively low.
Table IX
Susceptibility Results for ESBL Positive isolates by 
Agar Dilution method
Method MIC in microgram/ml 
Agar dilution method
CTAX
CTAX + 
CLA
CTAZ CTAZ + CLA
Resistant  isolates  ESBL 
producing (45)
4(8)
8(9)
16(9)
32(7)
64(7)
<128(5)
0.25
0.5
>0.25
0.5
>0.5
1
2(9)
16(7)
8(10)
4(7)
32(8)
64(4)
0.125
>0.5
0.5
0.25
0.5
>0.5
A fixed concentration of 4 micro gram of  clavulanic acid per ml 
was  used  in  conjunction  with  each  antimicrobial  agent.  Figures  in 
parentheses   =  (  )   Number  of  isolates,  CTAX  =  Cefotaxime, 
CTAZ =  Ceftazidime,  CLA  =  Clavulanic acid  
The  susceptibility  Results  for  ESBL  Positive  isolates  by  Agar 
Dilution method (MIC determination) were studied and analysed.  It was 
found that  there  was  a  decrease  of  >3 doubling  dilutions  in  MICs of 
cefotaxime,  ceftazidine  with  clavulanic  acid  compared  to  the  MIC of 
cefotaxime, ceftazidine alone.  
DISCUSSION
DISCUSSION
Of one hundred and twenty isolates – 45 were found to be ESBL 
producers. Which were screened and confirmed by NCCL methods.  This 
study, showed a prevalence rate of 37.5% of the total isolates of ESBLS, 
among Enterobactericeae in post operative wound infection (world wide 
prevalence <1 to 74%).  In India the prevalence rate varies from 28 to 
84% whereas is the U.S it was 0 to 25% and the national average is 3% 
(CDCNNIS) The high percentage of ESBL producing isolates (37.5%) 
deducted  in  this  study  may  be  due  to  selective  pressure  imposed  by 
extensive  use  of  antimicrobials  in  the  ICU  ward  and  Post  operative 
wards. The prevalence rate of ESBL detected in this study was 37.5%. 
But the prevalence rates deducted by both Priya Datta in a territory care 
hospital  in  India  and  Kanungo  et  al  Department  of  Micorbiology 
JIPMER, were 12.6% and 20.5% respectively which were found to be 
lower than the value reported in the study (32,18). But the prevalence rate 
reported by C. Rodrigues et al was 53% which was found to be higher 
than the value detected in this study (28).  The prevalence rate of ESBL 
producing Klebsiella pneumoniae detected in this study was 48.07%. But 
as per the studies of  Hansotia et al  in 1997, the prevalence of ESBL 
producing  Klebsiella isolates was detected as 76.5% (24) in central India 
which was found to be higher than this  study.  Kanungo et  al  in their 
studies stated that the prevalence of ESBL producing Klebsiella isolates 
was 43.75% (18) which was lower than the value reported in this study. 
The results of foreign studies have been studied by Subha et al in 2001. 
The incidence of ESBL producing Klebsiella isolates in the United States 
has been reported to the 5%. In France and England – 14 to 16% ESBL 
producing Klebsiella isolates have been reported. In a report from France, 
24.8% ESBL positive Klebsiella  pnemoniae  were found in patients  of 
more than 16 year of age. In another report from France – 3.5% of ESBL 
producing  Klebsiella pnemoniae was obtained in patients with a mean 
age of 66 year.  This shows that there is a wide disparity between Indian 
studies  and  Foreign  studies.  In  this  study  a  prevalence  of  ESBL 
producing Escherichia coli was identified as 46.50%. But Kanungo et al 
(18) and Anandhakrishna of JIPMER (18) in 2000 had reported incidence 
of 58.06% which was higher than the value of this study. Further they had 
reported  57.14%  for  ESBL  producing  Enetrobacter  species  (18). 
Sensitivity and Specificity of ESBL detection test – while referring the 
studies of Priya Datta it was found that a comparison of three test DDST, 
3 Dimensional Test  (3D) and IPT was made for the screening of ESBL 
strains (32). In their study IPT was found to be best screening method 
when  combined  with  use  of  a  ceftriaxone  disk.  IPT  detected  the 
maximum number of ESBL producing strains. Ceftriaxone detected the 
maximum ESBL rate in DDS, 3D and IPT followed by cefotaxine and 
ceftazidime (32). Courdron et al found the sensitivity of ceftriaxone to be 
88% ceftazidime 79% for these ESBL screening methods. Further it was 
confirmed  by  Hoe  et  al  studies  which  has  reported  IPT  was  100% 
sensitive and DDS was 96% sensitive (32). According to C.S. Anders – 
ESBL  detection  was  made,  in  their  study,  by  the  comparison  of  3 
Dimensional  Test  (3D)  and  double  disk  Test.  In  which  the  3D  test 
provided more  sensitivity  of  93% of the ESBL producing strains than 
Double Disk Test (26). By DDST, 76.5% of Klebsiellaisolates resistant to 
3G cephalosporins antibiotics was found to produce ESBLs, which was 
studied by Suba et al in 2002 in Central India (13). When analyzing the 
sensitivity  of  DDST it  was  found that  Thomson Sandars  has  reported 
DDS to be 79% sensitive, Vercauteren et al found the sensitivity to be 
93% and Shukla et al reported 90.6% sensitive, which were co-related 
with this study. Some studies questioned the sensitivity of Double Disk 
Test. Several modifications have been recommended including changing 
the distance between the Disks. A distance of 20mm center to center has 
been recommended by Priya Datta, Archana Thakkur in their study (32). 
A distance of 30 mm from center to center has been recommended by U. 
Chaudhry,  R.  Agarwal  (11).  The  MICs  of  most  cephalosporins  rose 
dramatically when the inoculum of susceptibility test was raised from 105 
to   107 CFU/ml.  which  was  found  by  Medeiros  and  Crellin.  It  was 
reported by Rasheed et al that the production  of that the production of 
SHV–1  in  a  strain  of  K.Pnemoniae  that  was  also  lacking  an  Outer 
membrane porin protein caused a false positive in ESBL detection tests 
that looked at the differential between the MICs of oxyimino – B lactum 
antibiotics with and without clavulanate.  The presence of an ESBL can 
also be masked by the expression of an Amp C. type enzyme in the same 
strain.  (Ref: above).
The prevalence of ESBLs in post operative wound infection may 
be reduced in  hospitals  by instituting a  hospital  infection control  cell, 
which will advise periodic Antibiotic rotation.  (Every 6 months).
Apart from this there was associated resistance to other antibiotics 
(Table  VIII).  The  enzymes  were disseminated  by  the  spread of  either 
plasmids or strains, as suggested by epidemiological studies. The location 
of  the  ESBL  genes  on  plasmids  may  also  explain  a  problem  of  co-
resistance. Such plasmid responsible for the development of Multi Drug 
Resistant  Strains  asa  they  may  also  carry  co-resistance  genes  to 
aminoglycosides, quinolones, co-timaxazome. In this study prevalence of 
ESBL was associated with a high degree of co-resistance to the above 
drugs, hence there is a necessasity for using alternate antibiotics to which 
these  organisms  may  be  susceptible.  Formulation  of  an  appropriate 
Hospital  Antibiotic  Policy will  be  necessary  to control  this  infections. 
Because  of  selective pressure  due to heavy use of  expanded spectrum 
cephalosporins  and  also  due  to  lapses  in  effective  infection  control 
measures, there are chances of increase of institutional out breaks. From 
one ESBL enzyme to another the optimal substrate profile may varies. 
For  this  reason  susceptibility  panels  with  one  extended  spectrum 
cephalosporins  cannot  predict  resistance  to  other  extended  spectrum 
cephalosporins.  NCCLS  has  recommended  use  of  more  than  one 
substrate  for  screening  (Ref.  32).  The  use  of  cefepime  allows  ESBL 
detection in isolates simultaneously producing Amp.c.
The findings detected in this study were co-related with risk factors 
like  prolonged  hospital  stay,  period  of  stay  in  SICU,  urinary 
catheterization for post operative patients, all of which will predispose to 
an out break. There was empirical prescription of Ampicilli, gentamicine 
and metronidazole for post operative patients. Ciprofloxacin, ceftriaxone 
or  ceftazidime  or  cefotaxine  was  added  later  on  which  will  lead  to 
prolonged hospital stay. The carbapenam antibiotics were not used at all. 
Further these ESBL strains will acquire co-resistance genes on plasmids. 
To  prevent  the  acquisition  of  these  infections,  precautionary 
measures should be taken – control of their spread by having an effective 
consistent  approach  to  surveillance  is  important.  Sensitivity  and 
specificity  of  ESBL deduction  test.  Even though there  are  merits  and 
shortcomings of each of the detection test Double disk approximation test 
of Jarlier et al and the Broth Dilution MIC reduction method (NCCLS 
confirmatory Test) are the easiest and cost effective methods for use in 
clinical  laboratories.  However  none  of  the  detection  test  are  100% 
sensitive and specific (30).
The techniques required for  the identification of the exact 
ESBL sub  type  –  DNA Probing  –  Polymerase  chain  reaction,  RFLP, 
Isoelectric focusing – are available only at research centers.  Perhaps with 
the  advent  of  gene  chip technology in  the near  future  –  the  sub type 
identification of ESBL and be made possible in future (32).              
CONcLUSION
CONCLUSION
    
The  prevalence  of  ESBL  producing  gram  negative  bacilli  in 
operative wound infection identified in this study was 37.50% which was 
with in the range of 28 to 84% reported in India 
ESBL production was found to  be coexsisted with resistance to 
several  other  antibiotics.  ESBLs are  encoded  by  plasmids  which  also 
carry co- resistant genes for other antibiotics. We found such associated 
co-resistance   with  cotrimaxazole,  44.66%  gentamicin,  38.73% 
ciprofloxacin,  41.09% oflaxacin  39.18%. Since  co-resistance  to  non  β 
lactum  antibiotics,  cotrimaxazole,  gentamicin  and  quinolones  was 
observed,  combination  of  Imipenem+amikacin  were  found  to  be 
alternatives  for  the  treatment  of  life  threatening  infections,  like 
septicemia,  hospital  acquired  pneumonia,  intravisceral  abscess  due  to 
faster killing rates of Amikacin. Our study highlights the emergence of 
ESBL producing Klebsiella pneumoniae (48.01%) isolates endowed with 
extremely wide spectrum of antibiotic resistance including resistance to 
cotrimaxazole, gentamicin and quinolones suggest that ESBL producing 
Klebsiella pneumoniae isolates have emerged as one of the major multi-
drug resistance organisms. In this study, prevalence of ESBL was found 
in 37.5% of the strains isolated from the surgical wounds with a high 
degree of associated co-resistance to non β lactum antibiotics. Therefore 
Formulation of an appropriate hospital antibiotic policy is necessary to 
control  these  infections.  Knowing  the  prevalence  of  ESBL  positive 
strains in a hospital environment will become necessary to formulate a 
policy of empirical therapy in high risk units (Ref. 11). 
Impact  of  post  discharge  surveilance  of  surgical  infections  in 
operative  surgery  is  a  very  important  factor.  Surveillance  feedback  to 
surgeons  is  important  in  reducing Surgical  Site  Infections  (SSIs)  post 
operative infection will be missed unless post discharge surveillance is 
undertaken.  (Ref :  Annals  of  the Royal  College Sergeants  of  England 
trainees presentation recommended by the college page 214- Department 
of   vascular  surgery  and  microbiology.  WORCESTERSHIRE  Royal 
Hospital U.K) which is essential to inform surgeons of their true rate in 
surgical  site  infections.  To  reduce  the  wound  sepsis  rate  (as  post 
operative  wound  closure  (primary  closure)  during  contaminated 
operations has been associated with nearly 40% wound sepsis rate based 
on Knightons wound severity index. (Knighton et al) and post surgical 
mortality  rate,  proper  deduction  and  timely  reporting  of  presence  of 
ESBL producing GNB in post operative wounds is very essential. It is 
suggested  that  routine  diagnosis  of  ESBL  producing  strains  in  post 
operative  wound  infections  has  to  be  carried  out  inorder  to  avoid 
undesired effects of multi-drug resistant ESBL producing  Klebsiella  by 
strict control of antibiotic usage. The restricted use of antibiotics will lead 
to  the  withdrawal  of  selective  pressure  and  resistant  bacteria  will  no 
longer survive in such settings. These findings were the net result of this 
study. Further studies will be required to substantiate these findings in the 
field of microbiology. 
  
SUMMARY
SUMMARY
 The results of this study suggest that the prevalence rate of ESBL 
producing gram negative bacilli in post operative wound infections 
was  37.5% which  was  within  the  range  of  28-84% reported  in 
India. 
 The prevalence of ESBL identified in this study was found to co-
exist  with  a  high  degree  of  co-resistance  to  non  β lactum 
antibiotics.  Therefore  formulation  of  an  appropriate  Hospital 
Antibiotic Policy is necessary to control this infections. 
 Over  use  of  β lactams  has  imposed  a  selective  pressure  on 
pathogens to acquire resistance genes and mutate  these confer  a 
border  range  of  activity.  The  following  few  points  may  m\be 
mentioned for the prevention and control of the spread of ESBLs. 
 By having an  effective  and  consistent  approach  to  surveillance, 
prevention  and  control  of  the  spread  of  ESBLs  will  be  made 
possible.
 Screening of all targeted population at high risk and all high risk 
unit admissions, implementation of Hand washing programmes and 
basic  cleaning of  all  surface  levels.  (Hand touch sites)  were  all 
necessary to control the spread. 
 Out break activities in the form of patient screening, placing them 
in contact precautions user barrier precautions are all necessary. 
 Our  study  highlights  emergence  of  ESBL  producing 
Klebsiella pneumoniae 48.01% isolates as one of the major multi 
drug resistant organisms. 
 A  multidisciplinary  approach  coordinated  participation  of 
microbiologists,  clinicians,  nursing  personnel,  hospital  infection 
control team is necessary for the management of ESBL producing 
infections. 
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aPPENDIX
APPENDIX
Media Composition 
Mueller  Hinton  Agar  :  this  medium  is  more  commonly  used  in 
conjunction  with high  potency  antibiotic  risk  for  the  determination  of 
antibiotic sensitivity patterns by the Kirby-Bauer technique : 
Beef infusion - 300 ml
Caesin hydrolysate - 17.5 g
Starch - 1.5 g
Agar - 10 g
Distilled Water - 1 Ltr.
Emulsify Starch in a small amount of cold water pour into the beef 
infusion  and  add  the  Caesin  hydrolysate  and  the  Agar.  Make  up  the 
volume to 1 liter with distilled water. Dissolve the constituents by heating 
gently at 100oC with agitation. Filter if necessary. Adjust the pH to 7.4. 
Dispense screw capped bottle and sterilize by autoclaving at 121oC for 20 
minutes.
MacConkey Agar : Useful medium for the cultivation of Enterobacteria 
Peptone - 20 g
Sodium taurocholate 
Commercial - 5 g
Water - 1 Ltr.
Agar - 20 gm
Neutral Red Solution - 2% in 50% ethanol = C 3.5 ml = Lactose 
10% aqueous solution = 100ml. Dissolve Peptone and taurocholate (Bile 
salt) in the water by heating. Add the Agar and dissolve it in the steamer 
or autoclave. Adjust the pH to 7.5. Add the lactose and neutral red and 
mix. Heat in the autoclave with free steam (100oC) for 1 hour then 115oC 
for 15 minutes. Pour Plates. 
Blood Agar :  The BDM is prepared by adding sterile blood to sterile 
nutrient agar that has been melted and cold to 50oC. 10% is the most 
usual  concentration  of  blood.  Horse  blood  is  the  commonest.  Double 
layer blood agar is usually the best. A thin layer of melted nutrient agar 
about  7  ml  for  a  9cm pertidish  is  poured and allowed to  set.  Then a 
similar thin layer of 10% blood agar is poured on top of the first layer. 
Nutrient Agar : Is nutrient brought solidified by the addition of agar. 
McFarland Standard : Preparation - McFarland Standard is  0.5  barium 
sulphate standard. Standard is prepared by adding 0.5ml of (w/v 1.17% 
Bacl2 Water) to 99.5 ml of (1% v/v H2So4). Aliquots of 4-6 ml of barium 
sulphate standard are distributed in screw capped bottles. Sealed and can 
be stored for six months in dark room and room temperature (20-28oC).
Gram Staining : Reagents : 
Primary Stain 
Crystal Violet - 10 g
Absolute alcohol - 100ml
Distilled water - 1 Ltr.
Mordant 
Iodine - 10 g
Potassium Iodide - 20 g
Distilled water - 1 Ltr.
Decolouriser - Acetone Alcohol Mixture
Acetone - 50ml
95% Ethanol - 50 ml
Counter stain
Carbol Fuschin Strong - 100ml
Distilled Water - 1 Ltr.
Specimen Processing  :  The specimens were processed  as  per  standard 
protocol for isolation of bacteria. 
Smear preparation : Grams Smear –
1. The clinical  material  was spread thinly and uniformly over a 
clean glass slide.
2. Smears  from  culture  on  solid  media  were  prepared  by 
emulsifying the colonies in a drop of saline placed on the slide 
and spread over thinly.
3. Smear was allowed to dry in air and then heat fixed by gently 
passing over a flame once or thrice. 
Gram Staining 
1. The heat fixed smear  was flooded with methyl violet kept for 
60 seconds.
2. The  stain  was  poured  off.  Then the  smear  was  washed with 
sterile distilled water covered with gram iodine for 60 seconds.
3. Again  the  smear  was  washed  with  distilled  water  and 
decolourised with acetone alcohol mixture for not more than 10 
seconds. 
4. The smear was washed with distilled water and counter stained 
with carbol fuschin for 30 seconds.
5. Then the smear was washed again with distilled water, air-dried 
and observation was made under oil immersion (100x).
